Be part of the knowledge.™

Pathology and Lab Medicine

58

LikeLikedUnlike

31-45 of 63

Emerging targeted therapy combination strategies in genitourinary malignancies
MinuteCE®
Emerging targeted therapy combination strategies in genitourinary malignancies
- Ignacio Duran, MD
  Peer
1.25 program credits
Emerging immunotherapy combination strategies in genitourinary malignancies
MinuteCE®
Emerging immunotherapy combination strategies in genitourinary malignancies
- Sandy Srinivas, MD
  Peer
1.25 program credits
Insights from global key opinion leaders on optimizing patient care in genitourinary malignancies
MinuteCE®
Insights from global key opinion leaders on optimizing patient care in genitourinary malignancies
- Ignacio Duran, MD
  Peer
- Wenxin Xu, MD
  Peer
1.25 program credits
The Evolving Role of MET TKIs in NSCLC
CME/CE
The Evolving Role of MET TKIs in NSCLC
- Gilberto de Lima Lopes, Jr, MD, MBA, FASCO
  Peer
- Jyoti Patel, MD
  Peer
0.75 credits
MinuteCE®
Precision Timing: Unveiling the Impact of CDK4/6 Inhibition in Early HR+/HER2- Breast Cancer
- Hope S. Rugo, MD, FASCO
  Peer
- Nadia Harbeck, MD, PhD
  Peer
1.25 credits 10 episodes
Treatment Intensification in HR+/HER2- EBC: Who and When?
MinuteCE®
Treatment Intensification in HR+/HER2- EBC: Who and When?
- Hope S. Rugo, MD, FASCO
  Peer
- Nadia Harbeck, MD, PhD
  Peer
1.25 program credits
advertisement
Endpoints in Adjuvant Breast Cancer Trials: Implications for Clinical Practice
MinuteCE®
Endpoints in Adjuvant Breast Cancer Trials: Implications for Clinical Practice
- Hope S. Rugo, MD, FASCO
  Peer
- Nadia Harbeck, MD, PhD
  Peer
1.25 program credits
Recent updates from adjuvant trials in HR+/HER2- EBC
MinuteCE®
Recent updates from adjuvant trials in HR+/HER2- EBC
- Nadia Harbeck, MD, PhD
  Peer
1.25 program credits
High-Risk, HR+/HER2- EBC: Mastering Treatment Selection
MinuteCE®
High-Risk, HR+/HER2- EBC: Mastering Treatment Selection
- Hope S. Rugo, MD, FASCO
  Peer
- Nadia Harbeck, MD, PhD
  Peer
1.25 program credits
Differentiating Safety Profiles of CDK4/6 Inhibitor Combination Regimens
MinuteCE®
Differentiating Safety Profiles of CDK4/6 Inhibitor Combination Regimens
- Hope S. Rugo, MD, FASCO
  Peer
- Nadia Harbeck, MD, PhD
  Peer
1.25 program credits
Interprofessional Coordination of Adverse Event Management
MinuteCE®
Interprofessional Coordination of Adverse Event Management
- Nadia Harbeck, MD, PhD
  Peer
1.25 program credits
Maximizing Adherence and Persistence via Patient Engagement
MinuteCE®
Maximizing Adherence and Persistence via Patient Engagement
- Hope S. Rugo, MD, FASCO
  Peer
- Nadia Harbeck, MD, PhD
  Peer
1.25 program credits
advertisement
Differentiating CDK4/6 Inhibitors in an Evolving European Treatment Landscape for High-Risk HR+/HER2- EBC
MinuteCE®
Differentiating CDK4/6 Inhibitors in an Evolving European Treatment Landscape for High-Risk HR+/HER2- EBC
- Nadia Harbeck, MD, PhD
  Peer
1.25 program credits
Case: A Patient With HR+/HER2- EBC at High-Risk for Recurrence
MinuteCE®
Case: A Patient With HR+/HER2- EBC at High-Risk for Recurrence
- Hope S. Rugo, MD, FASCO
  Peer
- Nadia Harbeck, MD, PhD
  Peer
1.25 program credits
Case: A Patient With High-Risk HR+/HER2- EBC Potentially Eligible for CDK4/6 and/or PARP Inhibitor
MinuteCE®
Case: A Patient With High-Risk HR+/HER2- EBC Potentially Eligible for CDK4/6 and/or PARP Inhibitor
- Hope S. Rugo, MD, FASCO
  Peer
- Nadia Harbeck, MD, PhD
  Peer
1.25 program credits

Program Chapters

Segment Chapters

Playlist:

Recommended